Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02186379 · ClinicalTrials.gov registry record · NA
Eating RePace Study
A NA study, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT02186379: Completed NA study, sponsored by Children's Hospital of Philadelphia.
NCT02186379 is a NA study that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 28 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02186379, a NA study, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
The aims of this study are to develop a novel family-based behavioral intervention (Re-Pace) to help children at risk for obesity (children who eat rapidly and have an overweight parent/legal guardian) develop a more normal eating rate.
Primary Outcome
The purpose of this randomized, controlled pilot study is to retrain children at risk for obesity (4-7 years of age in the 65th - \<96th BMI percentile for age and sex, who have rapid eating and an obese participating parent/legal guardian \[ N = 15\]) to reduce their rate of eating (mouthfuls/minute) during a laboratory test meal, compared with participants in usual care control condition (UCC),which receives a brief educational intervention to promote healthy eating after the final assessment)
Interventions
- BEHAVIORAL Usual Care Control
- BEHAVIORAL RePace Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-10 |
| Phase | NA |
What the finished NCT02186379 record still lists
NCT02186379 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Usual Care Control is the first listed.
NCT02186379 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02186379 about?
NCT02186379 is a clinical study titled "Eating RePace Study". The aims of this study are to develop a novel family-based behavioral intervention (Re-Pace) to help children at risk for obesity (children who eat rapidly and have an overweight parent/legal guardian) develop a more normal eating rate.
What is the current status of trial NCT02186379?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2012-11. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02186379?
The interventions under investigation include: Usual Care Control (BEHAVIORAL), RePace Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT02186379?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02186379's enrollment target sits among peer trials
28 1704th of 2000 higher than 293 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia